EGFR and non-small cell lung carcinoma: Co-occurring genomic alterations such as RB1 mutation, PTEN mutation, and MDM2 and CDK4/6 amplification are associated with worse PFS in patients with EGFR mutation-positive NSCLC [30, 31].